Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PAMELA D MOORE

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1598838435
CMS profile
118001
Location
PLANO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$266.59

11 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $167.59 10
Education $99.00 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Astellas Pharma US Inc $114.63 2
AbbVie Inc. $71.85 4
Amarin Pharma Inc. $19.39 1
Eisai Inc. $17.17 1
Merck Sharp & Dohme Corporation $17.13 1
Lilly USA, LLC $13.29 1
GlaxoSmithKline, LLC. $13.13 1

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PAMELA D MOORE

NPI 1598838435 · CMS profile ID 118001

Allopathic & Osteopathic Physicians / Internal Medicine

PLANO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1598838435?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PAMELA D MOORE, NPI 1598838435, CMS profile ID 118001. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1598838435?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). PAMELA D MOORE, NPI 1598838435, CMS profile ID 118001. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1598838435?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
PAMELA D MOORE, NPI 1598838435, CMS profile ID 118001, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1598838435?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

11 matching records · $266.59 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 11 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–11 of 11.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $18.5408/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795757735 CMS
AbbVie Inc. $14.3907/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795757729 CMS
Merck Sharp & Dohme Corporation $17.1307/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848435743 CMS
Amarin Pharma Inc. $19.3907/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815170215 CMS
Astellas Pharma US Inc $99.0007/20/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821456939 CMS
Lilly USA, LLC $13.2907/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818673737 CMS
Astellas Pharma US Inc $15.6307/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821456933 CMS
Eisai Inc. $17.1707/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817972993 CMS
AbbVie Inc. $23.0406/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795757721 CMS
GlaxoSmithKline, LLC. $13.1306/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803146471 CMS
AbbVie Inc. $15.8806/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795757715 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,374.14 113
PY2020 $293.54 19
PY2021 $266.59 11
PY2023 $38.13 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $150.00 1
PY2023 Principal investigator $81,329.92 42
PY2022 Principal investigator $230,331.53 69
PY2021 Principal investigator $235,861.88 64
PY2020 Principal investigator $331,535.42 56
PY2019 Principal investigator $588,251.30 60

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

42 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $6,900.00 10/10/2023 Non-covered Recipient Entity
Clinrx Research Joseph Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 1035933071
Principal investigator 1 SANOFI US SERVICES INC. $80.02 10/03/2023 Non-covered Recipient Entity
Clinrx Research Joseph Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 1035933059
Principal investigator 1 SANOFI US SERVICES INC. $3,750.00 09/05/2023 Non-covered Recipient Entity
Clinrx Research Joseph Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 1035933049
Principal investigator 1 SANOFI US SERVICES INC. $2,000.00 08/14/2023 Non-covered Recipient Entity
Clinrx Research Joseph Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 1035933039
Principal investigator 1 SANOFI US SERVICES INC. $2,000.00 07/24/2023 Non-covered Recipient Entity
Clinrx Research Joseph Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 1035933029
Principal investigator 1 ABBVIE INC. $1,379.40 07/11/2023 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Long-Term Safety Study of Elagolix in Combination With Estradiol;Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 998390237
Principal investigator 1 SANOFI US SERVICES INC. $750.00 07/10/2023 Non-covered Recipient Entity
Clinrx Research Joseph Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 1035932997
Principal investigator 1 SANOFI US SERVICES INC. $3,600.00 07/10/2023 Non-covered Recipient Entity
Clinrx Research Joseph Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 1035933007
Principal investigator 1 SANOFI US SERVICES INC. $50.00 07/10/2023 Non-covered Recipient Entity
Clinrx Research Joseph Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 1035933017
Principal investigator 1 GlaxoSmithKline, LLC. $1,230.25 06/14/2023 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 1006206397
Principal investigator 1 GlaxoSmithKline, LLC. $3,902.61 06/14/2023 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 1006206607
Principal investigator 1 ABBVIE INC. $1,220.40 06/08/2023 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Long-Term Safety Study of Elagolix in Combination With Estradiol;Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 998386091
Principal investigator 1 ABBVIE INC. $183.60 05/11/2023 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Long-Term Safety Study of Elagolix in Combination With Estradiol;Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 998382127
Principal investigator 1 GlaxoSmithKline, LLC. $1,622.97 05/03/2023 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 1006206391
Principal investigator 1 GlaxoSmithKline, LLC. $371.25 05/03/2023 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 1006206403
Principal investigator 1 ABBVIE INC. $2,500.00 04/05/2023 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 998376933
Principal investigator 1 ABBVIE INC. $750.00 03/30/2023 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 998376087
Principal investigator 1 SANOFI US SERVICES INC. $3,010.12 03/20/2023 Non-covered Recipient Entity
Clinrx Research Joseph Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 1035932967
Principal investigator 1 ABBVIE INC. $75.00 03/16/2023 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 998374545
Principal investigator 1 ABBVIE INC. $526.50 03/16/2023 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 998374923
Principal investigator 1 ABBVIE INC. $8,501.00 03/16/2023 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 998374925
Principal investigator 1 ABBVIE INC. $2,458.95 03/16/2023 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Long-Term Safety Study of Elagolix in Combination With Estradiol;Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 998374927
Principal investigator 1 ABBVIE INC. $2,278.00 03/16/2023 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 998374929
Principal investigator 1 ABBVIE INC. $10,168.20 03/03/2023 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 998372441
Principal investigator 1 GlaxoSmithKline, LLC. $1,100.00 03/03/2023 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 1006206601
Principal investigator 1 ABBVIE INC. $1,790.90 02/16/2023 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 998370961
Principal investigator 1 ABBVIE INC. $134.96 02/16/2023 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 998370989
Principal investigator 1 ABBVIE INC. $8,809.75 02/16/2023 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 998370991
Principal investigator 1 ABBVIE INC. $592.00 02/16/2023 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 998370993
Principal investigator 1 GlaxoSmithKline, LLC. $1,300.00 02/15/2023 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 1006206613
Principal investigator 1 GlaxoSmithKline, LLC. $337.50 02/15/2023 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 1006206639
Principal investigator 1 ABBVIE INC. $33.75 02/09/2023 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 998369425
Principal investigator 1 ABBVIE INC. $240.00 01/19/2023 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Long-Term Safety Study of Elagolix in Combination With Estradiol;Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 998366905
Principal investigator 1 GlaxoSmithKline, LLC. $200.00 01/18/2023 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 1006206409
Principal investigator 1 GlaxoSmithKline, LLC. $55.41 01/18/2023 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 1006206621
Principal investigator 1 ABBVIE INC. $343.25 01/12/2023 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 998365693
Principal investigator 1 ABBVIE INC. $2,658.10 01/12/2023 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Long-Term Safety Study of Elagolix in Combination With Estradiol;Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 998365695
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 01/11/2023 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 1006206633
Principal investigator 1 ABBVIE INC. $150.00 01/05/2023 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Long-Term Safety Study of Elagolix in Combination With Estradiol;Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 998363971
Principal investigator 1 ABBVIE INC. $51.03 01/05/2023 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Long-Term Safety Study of Elagolix in Combination With Estradiol;Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 998363973
Principal investigator 1 ABBVIE INC. $1,725.00 01/05/2023 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 998363975
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 01/03/2023 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 1006206627